Efficacy, Safety, and Tolerability of PF-06649751 in Parkinson’s Disease Patients at Early Stage of the Disease
A 15-Week, Phase 2, Double-Blind, Randomized, Placebo-Controlled, Flexible Dose Study to Investigate the
Efficacy, Safety and Tolerability of PF-06649751 in Subjects With Early Stage Parkinson’s Disease
Category & Conditions: Neurological Diseases and Conditions
Medicine: PF-06649751
ClinicalTrials.gov Identifier (NCT): NCT02847650
Protocol ID: B7601011
PrintDownloadOpen Plain Language Summary Result: Click here